Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

@article{Yu2010AntiGD2AW,
  title={Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.},
  author={Alice L. Yu and Andrew L Gilman and Mehmet Fevzi Ozkaynak and Wendy B. London and Susan G. Kreissman and Helen X. Chen and Malcolm A. Smith and Barry Douglas Anderson and Judith G Villablanca and Katherine K. Matthay and Hiroyuki Shimada and Stephan A. Grupp and Robert C. Seeger and C. Patrick Reynolds and Allen B. Buxton and Ralph A. Reisfeld and Stephen D Gillies and Susan L. Cohn and John M. Maris and Paul M. Sondel},
  journal={The New England journal of medicine},
  year={2010},
  volume={363 14},
  pages={
          1324-34
        }
}
BACKGROUND Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. [] Key MethodMETHODS Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive…

Figures and Tables from this paper

Pediatric Neuroblastoma: Combined Treatment with Monoclonal Antibody and Cytokines Preceded by Hematopoietic Stem Cell Transplantation
TLDR
Immunotherapy with ch14.18, GM-CSF, and IL-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma who achieved minimal residual disease status after intensive multimodal therapy.
Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study
TLDR
Evaluated the safety, tolerability, and antitumor activity of hu14.18-IL2 given in combination with GM-CSF and isotretinoin, finding that it is safe and tolerable.
Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma
TLDR
The substitution of IL15 for IL2 leads to significant tumor regression in vitro and in vivo and supports clinical testing of IL 15 for immunotherapy in pediatric neuroblastoma.
Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
TLDR
It is expected that anti-GD2 treatment can serve as a model for the use of monoclonal antibody immunotherapy against cancers in the future.
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
  • N. Cheung, I. Cheung, S. Modak
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
Retrospective analysis of consecutive trials from a single center demonstrated that MoAb 3F8 + GM-CSF + CRA is effective against chemotherapy-resistant marrow MRD.
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
TLDR
It is reported that the HDAC inhibitor Vorinostat synergizes with anti-GD2 mAb therapy in reducing NBL tumor growth, and implies further testing of other epigenetic modulators with immunotherapy and provides a strong basis for clinical testing of anti- GD2 plus Vor inostat combination therapy in NBL patients.
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
  • A. Heczey, C. Louis, M. Brenner
  • Medicine, Biology
    Molecular therapy : the journal of the American Society of Gene Therapy
  • 2017
G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
TLDR
Preclinical data support the use of G-CSF as an alternative stimulating cytokine to GM- CSF in the treatment of high-risk neuroblastoma with dinutuximab, warranting further testing of G -CSF in a clinical setting.
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
TLDR
This study confirmed the significant, but manageable treatment-related toxicities of this immunotherapy and identified possible cytokine biomarkers associated with select toxicities and outcome and EFS and OS appear similar to that previously reported on ANBL0032.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
  • N. Cheung, H. Lazarus, N. Berger
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1987
TLDR
In a phase I study, 3F8 was administered intravenously to 17 patients with metastatic GD2 positive neuroblastoma or malignant melanoma at doses of 5, 20, 50, and 100 mg/m2, and mixed responses ranged from complete clinical remissions to mixed responses.
Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.
  • A. Gilman, M. Ozkaynak, P. Sondel
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
The maximum tolerable dose (MTD) and toxicity of ch14.18 given in combination with interleukin-2 (IL-2) after high-dose chemotherapy (HDC)/stem-cell rescue (SCR) was found to be tolerable in the early post-HDC/SCR period.
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
  • M. Albertini, J. Hank, P. Sondel
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
We conducted a Phase IB trial of antidisialoganglioside chimeric 14. 18 (ch14.18) antibody and interleukin 2 (IL-2) to determine the maximal tolerated dose (MTD), immunological effects, antitumor
Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
  • M. Ozkaynak, P. Sondel, R. Seeger
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
TLDR
Ch14.18 can be administered with GM-CSF after HSCT in patients with neuroblastoma with manageable toxicities, and three dose-limiting toxicities were observed among six patients at 50 mg/m(2)/d: intractable neuropathic pain, grade 3 recurrent urticaria, and grade 4 vomiting.
A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group
TLDR
Hu14.18-IL2 (EMD 273063) can be administered safely with reversible toxicities in pediatric patients at doses that induce immune activation and three patients did show evidence of antitumor activity.
Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.
TLDR
With the dose schedule used, ch 14.18 appears to be clinically safe and effective, and repeated mAb administration was not associated with increased toxicities, and further clinical trials of mAb ch 15.18 in patients with neuroblastoma are warranted.
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.
  • T. Simon, B. Hero, F. Berthold
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Consolidation treatment of stage 4 neuroblastoma with ch14.18 was associated with considerable but manageable side effects and Multivariate analysis failed to demonstrate an advantage of antibody treatment for EFS and OS.
Enhanced Activity of Hu14.18-IL2 Immunocytokine against Murine NXS2 Neuroblastoma when Combined with Interleukin 2 Therapy
TLDR
Animals showing prolonged tumor eradication of established tumors after the combined hu14.18-IL2 plus IL-2 regimen exhibited a protective T-cell-dependent antitumor memory response against NXS2 rechallenge showed enhanced ability to prevent tumor recurrence.
Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.
TLDR
A mouse/human chimeric antibody was developed that reacts with the disialoganglioside GD2 on the surface of tumor cells of neuroectodermal origin that causes cytotoxicity of human effector cells against melanoma cells 50- to 100-fold more efficiently than 14.G2a-activated human C-mediated cytolysis of melanoma cell.
...
1
2
3
4
5
...